A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer

LESSONS LEARNED: Monotherapy with prexasertib demonstrated modest activity in BRCA wild‐type, recurrent triple‐negative breast cancer, highlighting the unmet need for combination treatment strategies. Neutropenia, anemia, and thrombocytopenia are common with the use of prexasertib but are manageable...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Gatti‐Mays, Margaret E., Karzai, Fatima H., Soltani, Sanaz N., Zimmer, Alexandra, Green, Jeffrey E., Lee, Min‐Jung, Trepel, Jane B., Yuno, Akira, Lipkowitz, Stanley, Nair, Jayakumar, McCoy, Ann, Lee, Jung‐Min
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7938394/
https://ncbi.nlm.nih.gov/pubmed/32510664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0491
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados